Chronic myeloid Leukaemia (CML) is a type of cancer that affects the blood and bone marrow. In CML the bone marrow produces too many white cells, called granulocytes. These cells, sometimes called blasts or leukaemic blasts, gradually crowd the bone marrow, interfering with normal blood cell production. Mer-418™ is a patent NCE that is used as first line and second line therapy for CML and is compared to Imatinib, Dasatinib and Nilotinib with superiority in many parameters. Mer-418™ molecule is an evidence based medicine with publications in the reliable American Society of Hematology.
Orally fast dissolving films are a new approach to oral drug delivery technology.
Nasal administration is a route in which drugs are delivered through the nose. The nasal cavity is covered by a thin mucosa which is well vascularised. Therefore, a drug molecule can be transferred quickly across the single epithelial cell...
Our patient’s safety is foremost in our minds and MEROVEN is an early adopter of the upcoming EU legislation against falsified medicines. The European Medicine Agency (EMA) has taken measures to help protect patients from falsified medicines and has set new regulations that introduce ‘safety features’ on packaging of medicines for human use.
